Opiant Pharmaceuticals, Inc.
$20.65+0.00%(+$0.00)
TickerSpark Score
82/100
83
Valuation
55
Profitability
100
Growth
72
Health
100
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPNT research report →
52-Week Range66% of range
Low $7.34
Current $20.65
High $27.36
Companywww.opiant.com
Opiant Pharmaceuticals, Inc. , a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses.
- CEO
- Roger Crystal
- IPO
- 2007
- Employees
- 37
- HQ
- Santa Monica, CA, US
Price Chart
-28.79% · this period
Valuation
- Market Cap
- $108.80M
- P/E
- 30.58
- P/S
- 2.67
- P/B
- 1.96
- EV/EBITDA
- 15.10
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 77.74%
- Op Margin
- 12.66%
- Net Margin
- 7.39%
- ROE
- 7.31%
- ROIC
- 8.00%
Growth & Income
- Revenue
- $40.73M · 48.62%
- Net Income
- $3.01M · 261.69%
- EPS
- $0.68 · 254.55%
- Op Income
- $5.16M
- FCF YoY
- 192.63%
Performance & Tape
- 52W High
- $27.36
- 52W Low
- $7.34
- 50D MA
- $20.50
- 200D MA
- $14.79
- Beta
- 0.83
- Avg Volume
- 72.36K
Get TickerSpark's AI analysis on OPNT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 2, 23 | Silver Gabrielle Alison | sell | 21,343 |
| Mar 2, 23 | Silver Gabrielle Alison | sell | 2,500 |
| Mar 2, 23 | Silver Gabrielle Alison | sell | 2,500 |
| Mar 2, 23 | Silver Gabrielle Alison | sell | 2,000 |
| Mar 2, 23 | Silver Gabrielle Alison | sell | 2,500 |
| Mar 2, 23 | Silver Gabrielle Alison | sell | 2,500 |
| Mar 2, 23 | Collard Craig A | sell | 53,822 |
| Mar 2, 23 | Collard Craig A | sell | 2,000 |
| Mar 2, 23 | Collard Craig A | sell | 2,500 |
| Mar 2, 23 | Collard Craig A | sell | 5,000 |
Our OPNT Coverage
We haven't published any research on OPNT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OPNT Report →